GlassScriptPhysician profile
Olu Oredugba
NPI 1215975115
$1,690.40
in general payments reported to CMS, 2019-2025
10 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $193 · 2021: $278 · 2022: $59.45 · 2023: $290 · 2024: $239 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $911 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $910.55 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $384.88 | 2024-2025 | Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $365.36 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $278.95 | 2019-2022 | |
| Amgen INC. | $251.25 | 2020-2025 | Krystexxa |
| Ardelyx, INC. | $237.99 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Lilly USA, LLC | $44.97 | 2022-2023 | Mounjaro |
| Intuitive Surgical, INC. | $43.53 | 2019 | |
| Horizon Therapeutics Plc | $32.87 | 2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $29.36 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $21.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olu Oredugba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.